Rebecca Chambers

Insider Reports History

Reporting-owner location: South San Francisco, CA
Latest reporting-owner signature: /s/ Jonathan Wygant as attorney-in-fact
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Rebecca Chambers

Form 4 holding Chief Financial Officer

VERACYTE, INC.

Security class: Common Stock
Shares / value: 166,025
Estimated value: $7,257,616
Report date: 04 Sep 2026
Price: $43.71
Ownership: Direct

Form 4 holding Chief Financial Officer

Outset Medical, Inc.

Security class: Common Stock
Shares / value: 13,597
Estimated value: $58,331
Report date: 24 Jun 2021
Price: $4.29
Ownership: Direct

Form 4 holding Director

Inari Medical, Inc.

Security class: Common Stock
Shares / value: 0
Estimated value: $0
Report date: 19 Feb 2025
Price: $0.4569
Ownership: Direct

Form 4 holding Director

Alamar Biosciences, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 140,612
Estimated value
Report date: 20 Apr 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Chief Financial Officer

Outset Medical, Inc.

Security class: Non-Qualified Stock Option (right to buy)
Shares / value: 77,745
Estimated value
Report date: 24 Jun 2021
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Rebecca Chambers

4 VCYT

VERACYTE, INC.

Report period: 02 Sep 2026
Transactions: 3
Transaction value: -$157,394
Accepted by SEC: 04 Sep 2026, 19:54
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 02 Jun 2026
Transactions: 3
Transaction value: -$177,083
Accepted by SEC: 04 Jun 2026, 21:38
Role: Chief Financial Officer
Next action: Open filing details

4 ALMR

Alamar Biosciences, Inc.

Report period: 20 Apr 2026
Transactions: 2
Transaction value: $0
Accepted by SEC: 20 Apr 2026, 20:37
Role: Director
Next action: Open filing details

3 ALMR

Alamar Biosciences, Inc.

Report period: 16 Apr 2026
Transactions: 0
Transaction value: $0
Accepted by SEC: 16 Apr 2026, 21:19
Role: Director
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 06 Mar 2026
Transactions: 2
Transaction value: $0
Accepted by SEC: 10 Mar 2026, 17:09
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 04 Mar 2026
Transactions: 2
Transaction value: -$662,869
Accepted by SEC: 06 Mar 2026, 16:33
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 02 Mar 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 04 Mar 2026, 16:16
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 26 Feb 2026
Transactions: 2
Transaction value: -$466,899
Accepted by SEC: 02 Mar 2026, 16:53
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 02 Dec 2025
Transactions: 3
Transaction value: -$778,161
Accepted by SEC: 04 Dec 2025, 19:44
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 05 Nov 2025
Transactions: 1
Transaction value: -$287,000
Accepted by SEC: 07 Nov 2025, 16:10
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 02 Sep 2025
Transactions: 1
Transaction value: -$161,721
Accepted by SEC: 04 Sep 2025, 17:45
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 02 Jun 2025
Transactions: 1
Transaction value: -$143,594
Accepted by SEC: 04 Jun 2025, 17:01
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 06 Mar 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 10 Mar 2025, 16:44
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 27 Feb 2025
Transactions: 3
Transaction value: -$787,861
Accepted by SEC: 03 Mar 2025, 16:30
Role: Chief Financial Officer
Next action: Open filing details

4

Inari Medical, Inc.

Report period: 19 Feb 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 19 Feb 2025, 19:56
Role: Director
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 03 Feb 2025
Transactions: 1
Transaction value: -$23,109
Accepted by SEC: 05 Feb 2025, 16:49
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 02 Dec 2024
Transactions: 2
Transaction value: -$455,454
Accepted by SEC: 04 Dec 2024, 16:59
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 12 Nov 2024
Transactions: 1
Transaction value: -$585,663
Accepted by SEC: 14 Nov 2024, 16:35
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 02 Sep 2024
Transactions: 1
Transaction value: -$109,289
Accepted by SEC: 04 Sep 2024, 20:24
Role: Chief Financial Officer
Next action: Open filing details

4

Inari Medical, Inc.

Report period: 21 Jun 2024
Transactions: 1
Transaction value: -$11,957
Accepted by SEC: 24 Jun 2024, 17:48
Role: Director
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 02 Jun 2024
Transactions: 1
Transaction value: -$71,836
Accepted by SEC: 04 Jun 2024, 16:43
Role: Chief Financial Officer
Next action: Open filing details

4

Inari Medical, Inc.

Report period: 20 May 2024
Transactions: 1
Transaction value: -$43,756
Accepted by SEC: 21 May 2024, 18:57
Role: Director
Next action: Open filing details

4

Inari Medical, Inc.

Report period: 24 Apr 2024
Transactions: 1
Transaction value: +$174,984
Accepted by SEC: 26 Apr 2024, 16:42
Role: Director
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 15 Mar 2024
Transactions: 2
Transaction value: -$46,188
Accepted by SEC: 19 Mar 2024, 16:50
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 06 Mar 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 08 Mar 2024, 16:36
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 02 Mar 2024
Transactions: 1
Transaction value: -$146,688
Accepted by SEC: 05 Mar 2024, 17:28
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 02 Dec 2023
Transactions: 1
Transaction value: -$47,772
Accepted by SEC: 05 Dec 2023, 16:44
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 02 Sep 2023
Transactions: 1
Transaction value: -$97,508
Accepted by SEC: 06 Sep 2023, 16:30
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 02 Jun 2023
Transactions: 1
Transaction value: -$31,610
Accepted by SEC: 06 Jun 2023, 16:48
Role: Chief Financial Officer
Next action: Open filing details

4

Inari Medical, Inc.

Report period: 18 May 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 19 May 2023, 17:55
Role: Director
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 06 Mar 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 09 Mar 2023, 18:09
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 02 Mar 2023
Transactions: 1
Transaction value: -$65,697
Accepted by SEC: 03 Mar 2023, 19:11
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 02 Dec 2022
Transactions: 1
Transaction value: -$21,418
Accepted by SEC: 06 Dec 2022, 16:14
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 02 Sep 2022
Transactions: 1
Transaction value: -$57,981
Accepted by SEC: 07 Sep 2022, 16:56
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 05 Aug 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 09 Aug 2022, 17:17
Role: Chief Financial Officer
Next action: Open filing details

4

Inari Medical, Inc.

Report period: 26 May 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 27 May 2022, 16:40
Role: Director
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 03 Mar 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 07 Mar 2022, 15:40
Role: Chief Financial Officer
Next action: Open filing details

4 VCYT

VERACYTE, INC.

Report period: 19 Jul 2021
Transactions: 2
Transaction value: $0
Accepted by SEC: 20 Jul 2021, 16:51
Role: Chief Financial Officer
Next action: Open filing details

3 VCYT

VERACYTE, INC.

Report period: 19 Jul 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 20 Jul 2021, 16:44
Role: Chief Financial Officer
Next action: Open filing details

4 OM

Outset Medical, Inc.

Report period: 24 Jun 2021
Transactions: 3
Transaction value: -$743,830
Accepted by SEC: 25 Jun 2021, 16:02
Role: Chief Financial Officer
Next action: Open filing details

3

Inari Medical, Inc.

Report period: 21 Jun 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 22 Jun 2021, 19:46
Role: Director
Next action: Open filing details

4

Inari Medical, Inc.

Report period: 21 Jun 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 22 Jun 2021, 19:45
Role: Director
Next action: Open filing details

4 OM

Outset Medical, Inc.

Report period: 25 May 2021
Transactions: 3
Transaction value: -$649,991
Accepted by SEC: 26 May 2021, 17:18
Role: Chief Financial Officer
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .